https://www.selleckchem.com/products/pcna-i1.html
The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable. In 2008 methyldibromo glutaronitrile (MDBGN) was banned from cosmetics in Europe and since then, the prevalence of allergy to it has progressively decreased. Nevertheless, it is still being tested in European baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients as well as the relevance of positive patch tests in a nationwide registry (R
Like
Comment
Share
